Vapotherm appoints Don Spence to its Board of Directors

– USA, NH –  Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary high-velocity therapy, which is used to treat patients of all ages suffering from respiratory distress, today announced the appointment of Donald Spence to its Board of Directors, effective October 21, 2020.

Mr. Spence will serve as a member and chair of the Compensation Committee, and as a member of the Audit Committee.

“We are delighted that Don is joining our Board of Directors. Don is a proven executive and his background in the healthcare industry, including his time leading the Home Healthcare Solutions business for Philips Respironics, will be invaluable as we continue to grow our business,” said CEO, Joe Army.

He added: “While at Respironics, Don led key initiatives in terms of setting the strategy, building the leadership team, launching new products, and rapidly growing the business in the home market, before its acquisition by Philips. We welcome him to the Vapotherm Board of Directors and we look forward to working with him as we continue to undertake our own growth initiatives.”

Vapotherm also announced that Craig Reynolds and Geoff Pardo have resigned from its Board of Directors. Mr. Reynolds joined the Board of Directors in 2010 and served as a member and chair of the Compensation Committee and as a member of the Nominating and Governance Committee. Mr. Pardo joined the Board of Directors in 2014 and served as a member of the Audit Committee.

“We are thankful for the commitment Craig and Geoff have made to the Company over the past several years. Craig’s executive experience and leadership skills were invaluable to the Board and management team as the Company began to scale its operations, launch new products, expand its commercial efforts, and build a strong corporate culture. Geoff’s executive experience and healthcare venture capital investing background were instrumental in helping the company develop and execute on its financing strategy, which helped fuel the Company’s growth,” said Board Chairman, Jim Liken. ”We wish them both the very best in their future endeavors.”

About Don Spence

Mr. Spence brings decades of leadership experience within the healthcare industry to the Vapotherm Board of Directors. Most recently, Mr. Spence served as President and CEO of Ebb Therapeutics, before retiring from the role in August 2019. Before joining Ebb, Mr. Spence was the Chairman and CEO at Lake Region Medical, where he worked from 2010 to 2015. Mr. Spence previously served as the CEO of Philips Healthcare, formerly Respironics Inc., from 2005 to 2010, where he was responsible for Philips Home Healthcare Solutions and integrating Respironics into Philips. Mr. Spence also has held several executive leadership roles within medical technology companies, including BOC Group, PLC – Datex Ohmeda Medical Systems.

Mr. Spence currently serves on the Board of Directors at Ebb Therapeutics, Integer Holdings, and Linguaflex.

Mr. Spence earned his B.A. in Economics from Michigan State University and his M.A. from Central Michigan University.

About Vapotherm, Inc.

Vapotherm, Inc. is a publicly-traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA. The company develops innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 2.3 million patients have been treated with Vapotherm high-velocity therapy.

Vapotherm high-velocity therapy is mask-free noninvasive ventilatory support and is a front-line tool for relieving respiratory distress—including hypercapnia, hypoxemia, and dyspnea. It allows for the fast, safe treatment of undifferentiated respiratory distress with one user-friendly tool. The Precision Flow system’s mask-free interface delivers optimally conditioned breathing gases, making it comfortable for patients and reducing the risks and care complexities associated with mask therapies. While being treated, patients can talk, eat, drink, and take oral medication.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.